MedPath

Moderate Alcohol Intake Among Patients With Type 2 Diabetes

Phase 2
Conditions
Type 2 Diabetes
Registration Number
NCT00295334
Lead Sponsor
The S. Daniel Abraham International Center for Health and Nutrition
Brief Summary

Our specific aim is to explore the effect of moderate alcohol intake on parameters of glycemic index and lipid profile among patients with type 2 diabetes.

Detailed Description

Successful long-term control of hyperglycemia decreases the risk for diabetic complications . Although a family history of diabetes is an established risk factor for type 2 diabetes, lifestyle factors also play an important role in its cause . However, physicians are poorly informed about how their patients' alcohol use affects risk for or management of diabetes. Moderate alcohol consumption has been associated with lower risk of both cardiovascular disease and type 2 diabetes, and is also linked to lower cardiovascular risk among type 2 diabetics. Potential mechanisms have focused primarily on lipid metabolism, coagulation, fibrinolysis, and insulin sensitivity. A recent systematic review of the literature to assess the effect of alcohol consumption on risk for and management and complications of diabetes mellitus suggests that moderate alcohol consumption is associated with a decreased risk for diabetes, whereas heavy alcohol consumption may be associated with an increased risk. Our aim is to assess the effect of moderate alcohol intake on glycemic control and cardiovascular disease mediators among patients with type 2 diabetes.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  1. Age between 40-75 yrs.
  2. Alcohol abstainers (less than or equal to 1 drink/week)
  3. Established diagnosis of type 2 diabetes.
  4. Clinically stable, with no stroke or MI within the last 3 months and no major surgery within the last 3 months.
Exclusion Criteria
  1. Taking Insulin >2 injections /day, or with insulin pump.

  2. TGs>500 mg/dL.

  3. HbA1c >10%

  4. Serum creatinine > 2 mg/dl

  5. Liver dysfunction (above 2 fold level of ALT and/or AST enzymes)

  6. Evidence of severe diabetes complications (such as proliferative retinopathy or renal disease).

  7. Patients with autonomic neuropathy manifested as postural hypertension and/or hypoglycemia unawareness. 7. Using drugs that might significantly interact with moderate alcohol. List of drugs will be obtained from pharmacology expert. 8. Presence of active cancer, receiving or had received chemotherapy in last 3 years.

  8. Suffering a major illness that might probably require hospitalization (upon physician's evaluation).

  9. Clinically assessed as having high potential of addictive behavior as judged by a validated clinical assessment and/or personal or family history of addiction, alcoholism or alcohol abuse.

  10. Severe symptoms during run-in as assessed by the physician. 12. Pregnant or lactating women. 13. Participation in another trial in which active intervention is being received.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
adherence, HbA1c, Glc
Secondary Outcome Measures
NameTimeMethod
LDL, HDL, TG
© Copyright 2025. All Rights Reserved by MedPath